 Eloxx Pharmaceuticals OTCMKTS:ELOX was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to investors on Tuesday, Zacks.com reports. The brokerage presently has a 3.50 price target on the stock. Zacks Investment Researchs price objective would indicate a potential upside of 21.53 from the companys current ... 